Literature DB >> 31101669

Healthy Donors Exhibit a CD4 T Cell Repertoire Specific to the Immunogenic Human Hormone H2-Relaxin before Injection.

Aurélien Azam1,2, Yann Gallais2, Sergio Mallart3, Stephane Illiano4, Olivier Duclos3, Catherine Prades1, Bernard Maillère5.   

Abstract

H2-relaxin (RLN2) is a two-chain peptide hormone structurally related to insulin with a therapeutic potential in multiple indications. However, multiple injections of human RLN2 induced anti-RLN2 Abs in patients, hampering its clinical development. As T cell activation is required to produce Abs, we wondered whether T cells specific for RLN2 might be already present in the human blood before any injection. We therefore quantified the RLN2-specific T cell repertoire using PBMCs collected from healthy donors. CD4 T cells were stimulated in multiple replicates by weekly rounds of stimulation by dendritic cells loaded with RLN2, and their specificity was assessed by IFN-γ ELISPOT. The number of specific T cell lines was used to estimate the frequency of circulating T cells. In vitro T cell response was demonstrated in 18 of the 23 healthy donors, leading to the generation of 70 independent RLN2-specific T cell lines. The mean frequency of RLN2-specific CD4 T cells was similar to that of T cells specific for known immunogenic therapeutic proteins. Using overlapping peptides, we identified multiple T cell epitopes hosted in the N-terminal parts of the α- and β-chains and common to multiple donors, in agreement with their capacity to bind to multiple HLA-DR molecules. Our results provide important clues to the immunogenicity of RLN2 and highlight the weak central immune tolerance induced against this self-hormone.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31101669     DOI: 10.4049/jimmunol.1800856

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Pegylation Reduces the Uptake of Certolizumab Pegol by Dendritic Cells and Epitope Presentation to T-Cells.

Authors:  Marie de Bourayne; Sylvain Meunier; Samuel Bitoun; Evelyne Correia; Xavier Mariette; Hervé Nozach; Bernard Maillère
Journal:  Front Immunol       Date:  2022-02-04       Impact factor: 7.561

Review 2.  Drug and Chemical Allergy: A Role for a Specific Naive T-Cell Repertoire?

Authors:  Rami Bechara; Alexia Feray; Marc Pallardy
Journal:  Front Immunol       Date:  2021-06-29       Impact factor: 7.561

Review 3.  Specificity of the T Cell Response to Protein Biopharmaceuticals.

Authors:  Sylvain Meunier; Marie de Bourayne; Moustafa Hamze; Aurélien Azam; Evelyne Correia; Catherine Menier; Bernard Maillère
Journal:  Front Immunol       Date:  2020-07-22       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.